The development of targeted therapy is an important advancement in cancer treatment. This session will review the application of next generation sequencing in oncology and compare testing methods. Participants will explore oncogenic driver mutations and FDA-approved targeted therapies in non-small cell lung cancer, along with management approaches for toxicities related to tyrosine kinase inhibitors.
- Provider:Horizon CME, Inc.
- Activity Link: http://default/node/1492
- Start Date: 2024-04-19 05:00:00
- End Date: 2024-04-19 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest